Search Results - ramakrishna+edupuganti

2 Results Sort By:
Covalent ERK inhibitors for suppressing cancer
BI-78D3, a small molecule, covalently binds to ERK1/2’s D-recruitment site, disrupting ERK signaling crucial for cancer cell growth. This shows promise for treating ERK-dependent cancers, including those resistant to BRAF inhibitors. This disrupts ERK signaling crucial for cell proliferation and survival, particularly in certain cancers like...
Published: 11/8/2024   |   Inventor(s): Kevin Dalby, Ramakrishna Edupuganti, Tamer Kaoud, Chelsea Massaro
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery, Life sciences > Therapeutics
Targeting MELK with indolinone derivatives
A promising strategy for treating triple-negative breast cancer and glioblastoma Indolinone derivatives inhibit MELK, an enzyme linked to cancer cell cycle regulation, proliferation, and apoptosis. These inhibitors show promise in treating cancers like triple-negative breast cancer and glioblastoma by selectively targeting MELK, reducing cancer cell...
Published: 9/11/2024   |   Inventor(s): Kevin Dalby, Ramakrishna Edupuganti
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation